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Abstract
Background: Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis
of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model
for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individuals carrying FAD
mutations can give valuable insights into the earliest stages of the disease where therapeutic interventions are
thought to be the most effective.
Methods: In the current cross-sectional study, products of APP processing (e.g., sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42)
were measured in the cerebrospinal fluid (CSF) of individuals carrying one of three FAD mutations, APPswe
(p.KM670/671NL), APParc (p.E693G) and PSEN1 (p.H163Y), as well as in non-mutation carriers from the same families.
Results: We observed pathological APP processing in presymptomatic carriers of FAD mutations, with different
profiles of APP and Aβ isoforms in the three mutation carrier groups, APPswe (p.KM670/671NL), APParc (p.E693G)
and PSEN1 (p.H163Y), except for the well-established decrease in CSF Aβ42 that was found with all mutations.
Conclusions: These findings add to the current evidence that AD pathophysiology differs between disease-causing
mutations and can be monitored in the presymptomatic disease stage by CSF analyses. This may also be important
from a therapeutic standpoint, by opening a window to monitor effects of disease-modifying drugs on AD
pathophysiology.
Keywords: Alzheimer’s disease, Amyloid precursor protein, Biomarkers, Cerebrospinal fluid, Genetics
Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder with pathological hallmarks in the brain,
including extracellular amyloid-beta (Aβ) plaques and
intracellular tangles of hyperphosphorylated tau protein.
According to the amyloid cascade hypothesis, accumula-
tion of Aβ in the brain is the driver of the disease
process [1]. Aβ isoforms ending at amino acid 42 (Aβ42)
are the most prone to aggregate, both into synaptotoxic
oligomers and into fibrils, which are the main compo-
nents of neuritic plaques [2]. Aβ is a product of the
cleavage of the amyloid precursor protein (APP) by the
proteases β-secretase (BACE1) and γ-secretase. Follow-
ing APP proteolysis at the cell surface, Aβ and sAPPβ,
are shed into the brain interstitial fluid, which communi-
cates freely with the cerebrospinal fluid (CSF). APP can
also be cleaved within its Aβ sequence by α-secretase in
a nonamyloidogenic pathway, releasing a different N-ter-
minal APP fragment, sAPPα [3].
The processing of APP is interesting from a thera-
peutic standpoint because modulation/inhibition at
different stages can be feasible to direct APP processing
towards the nonamyloidogenic pathway. Measuring the
products of APP processing in CSF can clarify how the
processing differs in vivo in individuals with AD path-
ology, compared with healthy controls. This is of
particular interest in patients who are still in the
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preclinical stage of AD, where disease-modifying drug
candidates are most likely to be successful.
To learn more about APP and Aβ metabolism in
familial AD (FAD), we measured sAPPα, sAPPβ, Aβ38,
Aβ40 and Aβ42 in the CSF of individuals carrying auto-
somal dominant FAD-causing mutations, comparing
them with noncarriers from the same families. Most of
the subjects were still in the preclinical stage of the dis-
ease. We included carriers of three different mutations,
APPswe [4, 5], APParc [6] and PSEN1 H163Y [7, 8], each
of which causes distinct changes in APP processing in
vitro. The effects of the different FAD mutations are il-
lustrated in Fig. 1.
Aβ42 is a well-established biomarker, which is decreased
in the CSF of individuals with AD, most probably due to
the accumulation of Aβ42 in the brain [9]. The same does
not apply to CSF Aβ40, which has been shown to be
unchanged in AD [10–12]. Previous studies have shown
conflicting results regarding the levels of other APP pro-
cessing products in AD. CSF Aβ38 has been reported
unchanged or increased in sporadic AD (SAD) [13, 14]
but decreased in FAD [15, 16]. Aβ16 has been shown to be
increased both in SAD and FAD [15, 16]. The levels of
sAPPα and sAPPβ have been reported to be similar in
FAD, SAD and controls [17, 18], but an increase in sAPPβ
has been observed when comparing SAD with frontotem-
poral dementia [19]. When patients with SAD were com-
pared with patients assessed as having other dementias
than AD, the SAD patients had increased levels of both
sAPPα and sAPPβ [20]. In contrast, one study reported a
decrease in sAPPα in carriers of the APPswe mutation
[21] and another a decrease both in sAPPα and sAPPβ in
patients with advanced AD compared with healthy
controls [10].
Here we speculated that the levels of the products of
APP processing would already be abnormal in preclinical
FAD and differ depending on the underlying mutation:
that the carriers of the APPswe mutation would have
increased levels of sAPPβ, Aβ38 and Aβ40 as well as de-
creased levels of sAPPα due to the increased affinity of
BACE1 to the mutated APP sequence; that the APParc
mutation carriers would have normal sAPPα and sAPPβ
levels but decreased levels of Aβ42, and potentially Aβ40
due to fibril formation; and that subjects with the PSEN1
H163Y mutation would also have normal levels of
sAPPα and sAPPβ, but decreased levels of Aβ38 as the
Fig. 1 Effects of the APPswe, APParc and PSEN1 H163Y mutations on APP processing in vitro. a APPswe mutation is located in the extracellular
domain of APP, at the BACE1 cleavage site, causing a 5–10-fold increase in the production of Aβ40 and Aβ42 [34]. Presenilin 1 is a subunit of the
γ-secretase and most PSEN1 mutations modulate the γ-secretase cleavage site-preference in a disease-promoting manner by inhibiting cleavages
at Gly37, Gly38 and Val39 in the Aβ sequence, without affecting the production of Aβ42 and Aβ40 significantly [35]. Finally, the arctic APP
mutation, located within the Aβ sequence, leads to the production of Aβ with higher propensity for protofibril formation than wild-type Aβ [6]. b
More detailed overview of the position of the APPswe and APParc mutations within APP. Letters, amino acids; numbers, position of the amino acids
within the APP sequence. c Schematic illustration of the transmembrane protein presenilin 1, a subunit of γ-secretase. The PSEN1 H163Y mutation
is located in the third transmembrane domain of the protein. APP amyloid precursor protein
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mutated γ-secretase preferentially produces Aβ40 and
Aβ42.
In the therapeutic sense it was interesting to see
whether these hypotheses would be correct or whether
we would find evidence of a common pathological
aspect of APP processing in carriers of the different FAD
mutations.
Finally, we calculated the sAPPβ/sAPPα ratio and the




Members of three Swedish families segregating three
known mutations leading to autosomal dominant AD,
APPswe (p.KM670/671NL), APParc (p.E693G) and
PSEN1 (p.H163Y), were included in the study. The aver-
age age at onset of the first clinically relevant symptoms
for each family is: 54 ± 4 years for APPswe (based on 19
affected cases), 56 ± 4 years for APParc (based on 12 af-
fected cases) and 51 ± 7 years for PSEN1 H163Y (based
on 11 affected cases). The average age at onset in each
family is normally distributed and is therefore presented
as a mean with standard deviation. Participants were re-
cruited to a longitudinal clinical and experimental FAD
study through the Genetics Unit, which provides genetic
counseling at the Memory Clinic at the Karolinska
University Hospital, and were examined between 1993
and 2011. The FAD study is a prospective study includ-
ing a thorough clinical evaluation, a comprehensive
neuropsychological test battery, neuroimaging (3Tesla
MRI), electroencephalography and biochemical assess-
ments, including collection of CSF. For AD diagnosis,
the criteria for dementia according to the National
Institute of Neurological Disorders and Stroke,
Washington DC, and Alzheimer Disease and Related
Disorders Association, Washington DC (NINCDS-
ADRDA) were used [22]; and for the diagnosis of mild
cognitive impairment (MCI) we used the criteria of the
International Working Group on Mild Cognitive Impair-
ment [23]. In a person with MCI the ability to perform
activities of daily living is preserved, while at the same
time there is evidence of cognitive decline either object-
ively measured over time or subjectively reported by the
individual/an informant in conjunction with objective
deficits. The study subjects are a subsample of individ-
uals at 50% risk of carrying one of the mutations leading
to FAD who gave informed written consent to and
underwent lumbar puncture (n = 36). The CSF was col-
lected at baseline/the entrance of each participant into
the study, during the time period of 1993–2011, and the
age of the participants presented in the following sec-
tions is the age at CSF collection. Of the 36 subjects
who underwent the procedure, 18 came from a family
segregating the APPswe mutation, 10 from a family seg-
regating the APParc mutation and eight from a family
segregating the PSEN1 H163Y mutation. All of the sub-
jects received genetic counseling in conjunction with
their participation in the study. The participants, clini-
cians and researchers involved in the study were blind to
the mutation status of the asymptomatic participants
unless the participant opted for presymptomatic genetic
testing (in a clinical genetics setting). All study proce-
dures were approved by the Regional Ethical Review
Board in Stockholm, Sweden.
Cerebrospinal fluid sampling
CSF samples were collected by lumbar puncture in the
L3/L4 or L4/L5 interspace at variable time points during
the day. According to current recommendations on CSF
sampling and handling, diurnal variation of AD
biomarkers should not be a concern [24]. Some of the
participants received premedication with 5 mg diazepam
and 1 g paracetamol prior to the procedure. Immediately
after collection the CSF was centrifuged at 2200 × g at
room temperature for 10 minutes. The supernatant was
collected and aliquoted into polypropylene cryotubes.
The aliquots used in the current study were stored at
−80 °C and had been thawed and refrozen once before
being thawed for analysis in this study.
Assay of sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42
The CSF samples were all analyzed at the same time by
electrochemiluminescence technology (Meso Scale
Discovery, Gaithersburg, MD, USA). An analysis of the
stability of the frozen CSF samples had been performed
previously and did not raise concerns. Concentrations of
Aβ38, Aβ40 and Aβ42 were analyzed using the MS6000
Human Abeta 3-Plex Ultra-Sensitive Kit (the 6E10
version), while β-secretase cleaved soluble APP (sAPP-β)
and α-secretase cleaved soluble APP (sAPP-α) in CSF
were analyzed using the MS6000 Human sAPPalpha/
sAPPbeta Kit, following the recommendations by the
manufacturer, and as described previously [25]. Because
the APPswe mutation changes the neo-epitope recog-
nized by the capturing antibody in the sAPPβ assay, CSF
sAPPβ levels in carriers of the APPswe mutation were
not included in the study.
Genetic analysis
Apolipoprotein E
The APOE genotyping was performed for SNPs rs7412
and rs429358 using TaqMan® SNP Genotyping Assays
(ABI, Foster City, CA, USA) according to the manufac-
turer’s protocol. The amplified products were run on
7500 fast Real-Time PCR Systems (ABI).
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Mutation analyses in APP and PSEN1
Exons 16 and 17 in APP were sequenced to screen for
the KM670/671NL and the E693G mutations [12, 14].
To confirm the H163Y mutation in PSEN1, exon 6 was
sequenced [26]. DNA was amplified using AmpliTaq
Gold® 360 PCR Master Mix (Applied Biosystems, Foster
City, CA, USA). Primer sequences and PCR conditions
are available upon request. The Big Dye® terminator v3.1
Cycle sequencing Kit (Applied Biosystems, Austin, TX,
USA) was used for Sanger sequencing. The exons in
APP and PSEN1 were sequenced in both directions and
analyzed on an ABI3500 Genetic Analyzer (Applied
Biosystems, Foster City).
Statistical analysis
Because of the fact that the age at symptom onset in
FAD varies between families, each subject’s age relative
to the mean age at clinical onset in their respective fam-
ily was calculated. Unpaired t tests and Pearson correla-
tions were applied to normally distributed data, while
the Mann–Whitney U test and Spearman correlations
were performed on data that was not normally distrib-
uted. The distribution of data was assessed with the
D’Agostino–Pearson normality test. Thus age, years to
predicted family specific clinical onset and CSF
biomarker levels were compared between noncarriers of
the FAD mutations and the mutation carrier group as a
whole as well as the noncarriers and carriers of each of
the three mutations separately. Fisher’s exact test was
used to compare gender and the frequency of the APOE
ε4 allele between the noncarriers and each of the
mutation carrier groups.
Exploratory Pearson/Spearman correlations were per-
formed between biomarker levels, as well as between
biomarker levels and predicted age at symptom onset.
Two-tailed p < 0.05 was considered significant.
Results
Demographics of the study population
Of the 36 subjects who underwent a lumbar puncture,
19 were mutation carriers (MC) and 17 were noncarriers
(NC). Of the MC, six carried a PSEN1 H163Y mutation,
four carried an APParc mutation and nine carried an
APPswe mutation (see Table 1 for a summary of the
demographic data of the study population). There was
no significant difference between the MC group as a
whole, or any of the MC subgroups, and the NC regard-
ing gender distribution, mean age or mean number of
years to predicted family specific onset. For the sake of
anonymity, the gender distribution in each mutation
group is not revealed in Table 1, because this could
cause certain participants to be able to deduct their mu-
tation status from the data. The PSEN1 carriers were
somewhat younger than the NC, but this difference did
not reach statistical significance. Furthermore, there was
no significant difference in the prevalence of APOE ε4
carriers between the NC group and the different MC
groups and there were only two individuals, a noncarrier
and a carrier of the APPswe mutation, who were APOE
ε4 homozygotes. At the time of CSF sampling, three of
the APPswe carriers fulfilled the diagnostic criteria for
AD with dementia, two APPswe carriers and one PSEN1
carrier fulfilled the criteria for MCI and the other 30
subjects (13 MC and 17 NC) were free of symptoms.
Levels of sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42
There was no significant difference in the levels of
sAPPα when comparing the MC group as a whole with
the NC. The same applied to sAPPβ when the PSEN1
and APParc carriers were grouped together and com-
pared with the NC. In contrast, all of the measured Aβ
isoforms, Aβ38, Aβ40 and Aβ42, were significantly lower
in the MC group. When the MC were grouped by their
specific mutation, a somewhat different pattern emerged.
The carriers of the APPswe mutation had significantly
lower levels of sAPPα than NC (note that APPswe MC
were not included in the analysis of CSF sAPPβ because
the end-specific capture antibody in the assay will not
react with sAPPβ modified at positions 670/671 by the
mutation), normal levels of Aβ38 and Aβ40 and signifi-
cantly decreased levels of Aβ42. The APParc carriers
shared the same pattern of the Aβ isoforms as the
APPswe carriers, but had normal levels of sAPPα and
high sAPPβ levels. Finally, the PSEN1 carriers had low
levels of both Aβ38 and Aβ42, and normal levels of Aβ40,
Table 1 Demographics of the study population
All MC (n = 19) APPswe (n = 9) APParc (n = 4) PSEN1 (n = 6) NC (n = 17)
Age (SD) 46.7 (11.9) 51.2 (12.1) 50 (6.6) 33.7 (7.0) 47.8 (10.2)
Years to onset (SD) −7.7 (12.3) −1.8 (12.1) −7 (6.6) −21.3 (7.0) −6.9 (9.9)
ApoE ε4 carrier 9/19 5/9 1/4 3/6 7/17
Normal cognition 13/19 4/9 4/4 5/6 17/17
MCI 3 2 - 1 -
AD 3 3 - - -
AD Alzheimer’s disease, MC mutation carriers, MCI mild cognitive impairment, NC noncarriers
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sAPPα and sAPPβ. See Fig. 2 for a summary of the levels
of the APP processing products.
These calculations were repeated after excluding all
subjects with MCI or AD diagnosis. This did not change
the results for the levels of sAPPα, sAPPβ and Aβ42, with
all of the significant differences in Fig. 2 remaining sig-
nificant. The levels of Aβ38 were no longer significantly
lower in the MC group as a whole when subjects with
MCI and AD had been excluded, but remained signifi-
cantly low in the PSEN1 carrier group. The results for
Aβ40 remained unchanged after removing MCI and AD
subjects, except the Aβ40 levels of the PSEN1 carriers,
which were significantly lower than in the NC when the
PSEN1 carrier with MCI diagnosis was excluded.
sAPPβ/sAPPα ratio and Aβ42/Aβ40 ratio
There was no significant difference in the sAPPβ/sAPPα
ratio when comparing the PSEN1 and APParc carriers
with the NC, irrespective of whether the NC were com-
pared with the MC as a whole or with a subgroup with a
specific mutation. The same applied when the NC were
compared with the presymptomatic PSEN1 carriers only
(data not shown).
The Aβ42/Aβ40 ratio was significantly lower in the
MC group as a whole than in the NC group (0.05 vs
0.11, p < 0.0001). The same applied to all the subgroups,
the APPswe carriers vs the NC (0.04 vs 0.11 p < 0.0001),
the presymptomatic APPswe carriers vs the NC (0.05 vs
0.11, p = 0.002), the APParc carriers vs the NC (0.03 vs
0.11, p < 0.001), the PSEN1 carriers vs the NC (0.07 vs
0.11, p < 0.01) and the presymptomatic PSEN1 carriers
vs the NC (0.07 vs 0.11, p < 0.01).
Correlations between the different products of APP
processing
Because of the small size of the APParc mutation carrier
group (n = 4) no correlation calculations were performed
involving that group alone. As has been reported previ-
ously [27], there was a positive correlation between
sAPPα and sAPPβ in the MC group as a whole (exclud-
ing the APPswe carriers as explained earlier), as well as
in the NC group. When looking only at the PSEN1
Fig. 2 CSF levels of sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42 in carriers of three FAD mutations. Scatter plots showing levels of sAPPα, sAPPβ, Aβ38,
Aβ40 and Aβ42 in carriers of three different mutations leading to FAD compared with healthy family members (NC). The mutation carriers were
compared with the NC as one group (MC) and by type of mutation (APPswe, APParc and PSEN1). Only carriers of the APParc and PSEN1 mutations
are included in the calculation of the mean level of sAPPβ. The biomarker levels in the NC group were normally distributed, except for sAPPβ.
Thus, the Mann–Whitney U test was used when comparing sAPPβ between groups. Also, the Mann–Whitney U test was used when comparing
the APParc and PSEN1 carriers with the NC due to the small sample sizes of these two MC groups. The unpaired t test was used for the rest of
the data, except when comparing Aβ42 between the NC and MC and comparing sAPPα between the NC and APPswe (here we used the
Mann–Whitney U test because these data were not normally distributed). Aβ amyloid beta, MC mutation carriers, NC noncarriers
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carriers, this correlation failed to reach significance,
probably due to the small number of individuals in the
group.
A strong positive correlation was observed between
Aβ38 and Aβ40 in all groups. There was a significant
correlation between Aβ40 and Aβ42 as well, in all groups
except the PSEN1 carriers. Interestingly, there was a
positive correlation between sAPPα and all the measured
Aβ isoforms in the NC group, but not in any of the
mutation carrier groups. Also, the NC group was the
only group showing a significant positive correlation
between Aβ38 and Aβ42.
The correlations between sAPPα, sAPPβ, Aβ38, Aβ40
and Aβ42 are summarized in Table 2.
Correlations between sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42
and years to expected symptom onset
Correlations between sAPPα, sAPPβ, Aβ38, Aβ40, Aβ42
and years to expected symptom onset were calculated to
see whether the levels of these markers changed as
the onset of symptoms approached. No such changes
were observed in any of the five markers in the whole
MC group, the PSEN1 group or in the NC group. In
the APPswe mutation carriers, the concentration of
Aβ38 (r = −0.69, p = 0.04), Aβ40 (r = −0.67, p = 0.05)
and Aβ42 (r = −0.86, p < 0.01) decreased significantly
when the expected symptom onset approached and
beyond (see Fig. 3). When subjects with a dementia
diagnosis were excluded from the APPswe mutation
carrier group these correlations failed to reach signifi-
cance, apart from Aβ42, which still showed a decrease
as age at onset approached (r = −0.85, p = 0.03). It was
not possible to repeat this calculation with only pre-
symptomatic APPswe mutation carriers because their
number is too small.
Correction for multiple comparisons
All of the significant correlations presented in Table 2
remained significant after correcting for multiple com-
parisons using the false discovery rate (FDR) correction.
The same applied to the biomarker levels presented in
Fig. 2, except for the low Aβ38 levels in the MC and the
PSEN1 groups and the low Aβ40 levels in the MC group
which did not survive this correction.
Discussion
Compared with noncarriers, carriers of the APPswe
mutation have significantly decreased CSF levels of
Table 2 Correlations between the products of APP processing in FAD mutation carriers
CSF biomarker sAPPα sAPPβ Aβ38 Aβ40 Aβ42
MC sAPPα 0.87 (<0.01) 0.2 (0.4) 0.09 (0.7) -0.2 (0.4)
sAPPβ 0.87 (<0.01) 0.2 (0.3) 0.1 (0.6) -0.2 (0.5)
Aβ38 0.2 (0.4) 0.2 (0.3) 0.93 (<0.0001) 0.44 (0.06)
Aβ40 0.09 (0.7) 0.1 (0.6) 0.93 (<0.0001) 0.6 (0.01)
Aβ42 -0.2 (0.4) -0.2 (0.5) 0.44 (0.06) 0.6 (0.01)
APPswe sAPPα 0.2 (0.6) 0.2 (0.7) -0.03 (0.9)
sAPPβ n.a. n.a. n.a. n.a. n.a.
Aβ38 0.2 (0.6) 0.9 (<0.001) 0.7 (0.06)
Aβ40 0.2 (0.7) 0.9 (<0.001) 0.8 (0.01)
Aβ42 -0.03 (0.9) 0.7 (0.06) 0.8 (0.01)
PSEN1 sAPPα 0.66 (0.18) 0.20 (0.7) 0.20 (0.7) 0.086 (0.9)
sAPPβ 0.66 (0.18) 0.60 (0.2) 0.60 (0.2) 0.54 (0.3)
Aβ38 0.20 (0.7) 0.60 (0.2) 1 (<0.01) 0.83 (0.06)
Aβ40 0.20 (0.7) 0.60 (0.2) 1 (<0.01) 0.83 (0.06)
Aβ42 0.086 (0.9) 0.54 (0.3) 0.83 (0.06) 0.83 (0.06)
NC sAPPα 0.64 (<0.01) 0.71 (<0.01) 0.72 (<0.01) 0.65 (<0.01)
sAPPβ 0.64 (<0.01) 0.28 (0.3) 0.33 (0.2) 0.29 (0.3)
Aβ38 0.71 (<0.01) 0.28 (0.3) 0.98 (<0.0001) 0.95 (<0.0001)
Aβ40 0.72 (<0.01) 0.33 (0.2) 0.98 (<0.0001) 0.98 (<0.0001)
Aβ42 0.65 (<0.01) 0.29 (0.3) 0.95 (<0.0001) 0.98 (<0.0001)
Correlations between the products of APP processing in the mutation carrier group as a whole (MC), carriers of the APPswe and PSEN1 mutations separately and in
the nonmutation carriers (NC)
Numbers represent Pearson/Spearman correlation coefficients (p values) (significant correlations in italics)
APP amyloid precursor protein, FAD familial Alzheimer’s disease, Aβ amyloid beta, MC mutation carriers, NC noncarriers
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sAPPα and Aβ42 whereas the levels of Aβ38 and Aβ40
were not significantly different. The decreased levels of
Aβ42 are expected, because Aβ42 is a well-established
AD biomarker and has been shown to be decreased in
AD patients in numerous studies [9]. The sAPPα levels
have also been shown to be reduced in a previous study
on some of the same individuals [21]. This could be due
to the increased activity of the amyloidogenic pathway of
APP processing in APPswe carriers at the expense of the
nonamyloidogenic pathway in which sAPPα is produced.
In the PSEN1 carriers the CSF levels of sAPPα and
sAPPβ were unchanged, whereas sAPPβ was increased
in the APParc carriers. The APParc carriers also showed
the expected decrease in Aβ42 levels, while both Aβ38
and Aβ42 were decreased in the PSEN1 carriers. The de-
crease in Aβ38 has been observed in previous studies on
PSEN1 carriers [15, 16] and the same applies to the nor-
mal levels of sAPPα and sAPPβ in the PSEN1 carriers
[17, 18]. Amyloid plaques including Aβ38 deposits, have
been shown to be limited to FAD cases and this accu-
mulation of Aβ38 in the brain could explain the low
levels Aβ38 in CSF [28]. Another, possibly coexisting,
explanation could be that the mutated γ-secretase pref-
erentially produces Aβ40 and Aβ42, at the expense of
Aβ38. The decrease in Aβ38 levels seems quite robust,
remaining significant when only presymptomatic PSEN1
carriers were included. In contrast, the observed reduced
levels of Aβ38 for the whole MC group were no longer
significantly low when looking only at presymptomatic
individuals. Taken together our results emphasize the
differences in production and metabolism of Aβ iso-
forms in different FAD mutations. The results for the
PSEN1 and APParc carriers fit our hypothesis quite
nicely, apart from the observed increased levels of
sAPPβ in the APParc carriers. A possible explanation for
this observation might be that increased fibril formation
and lack of monomeric Aβ isoforms somehow stimulates
amyloidogenic APP processing.
When looking at correlations between years to symp-
tom onset and the different APP processing products it
is interesting to see that the products remain stable in
subjects at different time points from expected onset in
the MC group as a whole and in the PSEN1 carriers
alone. The Aβ isoforms remained low in the MC
compared with the NC, while there was no difference in
the levels of sAPPα and sAPPβ in the MC and the NC.
Very few studies have looked at APP processing in
preclinical FAD [15–17] and to our knowledge none
have correlated the APP processing products to years to
symptom onset.
According to one study on SAD, there were no differ-
ences in BACE1 activity, sAPPα, sAPPβ and Aβ40 con-
centrations between AD patients and controls until the
levels of all of these biomarkers dropped in advanced
stages of AD [10]. The only mutation carrier group in
the current study that showed a change in these bio-
markers in relation to expected symptom onset was the
APPswe group, in which the levels of all of the Aβ iso-
forms decreased with progression of the disease. This
resonates quite well with the study by Rosen et al. [10]
on SAD, because the APPswe mutation carriers were the
only group including individuals that already had a
dementia diagnosis. The correlation ceased to be signifi-
cant when the subjects with dementia were excluded,
apart from Aβ42, which still showed a decrease over
time. A longitudinal study on the subjects included here
is ongoing and may shed light on the changes in these
markers over time through repeated sampling from the
same individuals.
We replicated the previously observed positive correl-
ation between sAPPα and sAPPβ in both the MC group
(excluding the APPswe carriers) and the NC group. This
observation correlates well with other studies including
healthy individuals as well as subjects with MCI, FAD
and SAD, suggesting that the α and β pathways are
noncompetitive [17, 20, 26, 27, 29, 30]. This positive cor-
relation also applies to the MC in this study, possibly ex-
cluding the APPswe carriers because they had low levels
of sAPPα. Because of limitations in the sAPPβ assay we
do not have information on the levels of sAPPβ in the
APPswe carriers and therefore can only speculate on the
correlation between sAPPα and sAPPβ in this group. It
is interesting that all three Aβ isoforms are positively
correlated to sAPPα but not to sAPPβ in the NC group,
as sAPPα is not a product of the same APP cleaving
pathway as Aβ. A possible explanation would be that all
Fig. 3 APPswe: correlations between years to onset and Aβ species.
Pearson correlations between the Aβ isoforms Aβ38, Aβ40 and Aβ42
and years to expected onset of the first clinically relevant symptoms
of FAD in carriers of the APPswe mutation. X axis, −10 represents an
individual with 10 years left to the expected onset (which is set to 0)
while 10 represents an individual 10 years past the expected onset.
All three correlations were significant, Aβ38 (r = −0.69, p = 0.04), Aβ40
(r = −0.67, p = 0.05) and Aβ42 (r = −0.86, p < 0.01), decreasing in
subjects sampled closer to the expected onset. Aβ amyloid beta
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of the measured Aβ isoforms are more abundant in the
CSF of healthy individuals with high levels of sAPPα, as
the threshold for Aβ aggregation in the brain has not yet
been reached. Aβ38 and Aβ40 have a positive correlation
to each other and the same is true for Aβ40 and Aβ42.
This suggests that the Aβ42 decrease in CSF in FAD may
be accompanied by a decrease in Aβ40 and possibly in
Aβ38 as well, although the current study failed to show a
significant correlation between Aβ42 and Aβ38.
Finally, we did not observe a difference in the sAPPβ/
sAPPα ratio between the MC and the NC. The sAPPβ/
sAPPα ratio has been suggested as a biomarker for brain
amyloidosis [30], but our findings do not support it as a
marker of early pathology. This should be interpreted
with caution, however, because the possibility remains
that the results were negative due to the small sample
size in this instance (only 10 MC from the PSEN1 and
APParc families because data on sAPPβ were not
included from the APPswe MC). As expected, the Aβ42/
Aβ40 ratio was low in the MC group as a whole and in
the MC subgroups compared with the NC. This differ-
ence remained statistically significant when symptomatic
individuals had been excluded, supporting its role as a
robust early AD biomarker.
The method used in the current study to measure the
potential biomarkers sAPPβ and sAPPα has recently
been analytically validated using novel standard operat-
ing procedures developed within the BIOMARKAPD
project [31]. This validation increases the credibility of
the results obtained with this method and decreases the
likelihood of analysis bias.
The results discussed were not corrected for multiple
comparisons and the differences observed in Aβ38 and
Aβ40 levels between groups did not survive a FDR
correction. When interpreting the results of the FDR cor-
rection one should keep in mind that the study was hypoth-
esis driven and the biomarkers carefully selected before any
statistical analysis was performed. Therefore, the study de-
sign itself reduces the likelihood of false positives. Also, the
small sample sizes, which often require nonparametric test-
ing, already reduce the power to detect true differences
between groups. The possibility still remains that the differ-
ences observed in Aβ38 and Aβ40 levels between groups
were significant by chance, as suggested by the FDR correc-
tion. However, we feel that this possibility is not great
enough to disregard the results altogether and that they
warrant further study in larger cohorts.
A limitation to this study is the number of included
subjects and this should be taken into account when
interpreting the results. The current study, however, is
larger than previous studies on other aspects of APP
processing which have included FAD subjects and repli-
cates some of their results, underlining the robustness of
the data acquired from this population. Even though the
small sample size might have had some effect on the
outcomes presented here, they are at the very least
strongly hypothesis generating. Another limitation is the
cross-sectional design of the study, which makes it im-
possible to assess changes in APP processing products
over time. This will be addressed in a longitudinal study
on the same subjects, which is ongoing. The usefulness
of FAD subjects as models for SAD has been supported
by several studies [32], but the possibility still exists that
these results might not be generalizable to SAD.
Conclusion
We observed pathological APP processing in presymp-
tomatic carriers of FAD mutations, which adds to the
current evidence that AD pathogenesis is present before
the development of clinical symptoms [33]. We found
no apparent common aspect of APP processing in the
three mutation carrier groups, apart from the well-
known decrease in CSF Aβ42, which is an early event in
AD pathogenesis. Perhaps this decrease is secondary to
the aggregation of brain amyloid, rather than a result of
the APP processing steps, and thus a poor marker for
the primary etiology. If the same type of treatment was
to be used in presymptomatic FAD mutation carriers re-
gardless of the type of mutation, these results suggest
that a treatment interfering with the final product of
APP processing, Aβ, would be a feasible option.
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